Objective To develop and validate a volume-based, quantitative imaging marker by integrating multi-parametric MR images for predicting glioblastoma survival, and to investigate its relationship and synergy with molecular characteristics. Methods We retrospectively analysed 108 patients with primary glioblastoma. The discovery cohort consisted of 62 patients from the cancer genome atlas (TCGA). Another 46 patients comprising 30 from TCGA and 16 internally were used for independent validation. Based on integrated analyses of T1-weighted contrast-enhanced (T1-c) and diffusionweighted MR images, we identified an intratumoral subregion with both high T1-c and low ADC, and accordingly defined a high-risk volume (HRV). We evaluated its prognostic value and biological significance with genomic data. Results On both discovery and validation cohorts, HRV predicted overall survival (OS) (concordance index: 0.642 and 0.653, P < 0.001 and P = 0.038, respectively). HRV stratified patients within the proneural molecular subtype (log-rank P = 0.040, hazard ratio = 2.787). We observed different OS among patients depending on their MGMT methylation status and HRV (log-rank P = 0.011). Patients with unmethylated MGMT and high HRV had significantly shorter survival (median survival: 9.3 vs. 18.4 months, log-rank P = 0.002). Conclusion Volume of the high-risk intratumoral subregion identified on multi-parametric MRI predicts glioblastoma survival, and may provide complementary value to genomic information. Key points • High-risk volume (HRV) defined on multi-parametric MRI predicted GBM survival.
Introduction
Glioblastoma (GBM) is the most deadly primary brain tumour in adults, with a median survival of 12-15 months despite aggressive treatment [1] . GBM is also a biologically heterogeneous disease, where four subtypes, i.e. proneural, neural, classical and mesenchymal subtypes, have been proposed based on molecular characteristics of the tumour [2] . Compared with the molecular approach, imaging provides a unique opportunity to noninvasively interrogate the anatomical and functional properties of the entire tumour. Given the routine use of imaging in GBM management, reliable imaging-based biomarkers would have tremendous value in precision medicine, by stratifying patients to guide individualized therapy.
There has been a significant interest in predicting survival of GBM patients based on multi-parametric magnetic resonance (MR) imaging that incorporates perfusion-weighted imaging [3] [4] [5] or diffusion-weighted (DW) imaging [6] [7] [8] [9] [10] [11] [12] . Most previous studies defined imaging prognosticators as a single point on the signal intensity histogram, e.g. maximum cerebral blood volume (CBV) [3] , minimum apparent diffusion coefficient (ADC) [13] or simple quantiles [6] . On the other hand, volume-based imaging metrics that incorporate both intensity and volumetric information may be more reliable indicators of tumour burden [14] [15] [16] . Furthermore, given the heterogeneous nature of GBM, detecting 'high-risk' intratumoral subregions could potentially identify biological relevant, aggressive subclones within a tumour [17] , and has therapeutic implications for intensified local therapy to improve survival [18] .
Recent preliminary studies have shown promising results for predicting survival of GBM patients based on analysis of intratumoral subregions, using conventional T1-weighted contrast-enhanced (T1-c) and T2-weighted fluid-attenuated inversion recovery (FLAIR) MR images [19, 20] . However, a method to explicitly identify clinically relevant, high-risk tumour volume with robust and meaningful cutoffs has been lacking. Current MR imaging markers based on simple, predefined cutoffs such as median or quantile may not be optimal. In addition, individual cutoffs at the patient level can be sensitive to variations due to differences in image acquisition protocols in different patients [21, 22] . Consequently, these imaging markers are difficult to compare and reproduce across cohorts in multicentre settings, which is a significant hurdle to their clinical translation.
In this study, we hypothesized that the volume of an intratumoral subregion associated with abnormally high signal intensity on T1-weighted contrast-enhanced imaging and abnormally low ADC on DW imaging can quantify the most aggressive disease burden within a tumour, and thus may be a better predictor of prognosis of GBM patients compared with whole-tumour imaging metrics. This is supported by recent studies showing that the tumour-enhancing volume [14] and the volume of low ADC [16] were both prognostic of overall survival (OS) in GBM. Instead of using predefined cutoffs for individual patients, we propose a novel method to define robust cutoffs applicable to the entire study population and identify high-risk intratumoral subregions by using a datadriven approach. Further, we evaluated the biological significance of our imaging marker through association with underlying molecular features. As opposed to most previous radiogenomic studies [23] [24] [25] [26] , we further investigated whether this imaging marker provides complementary value to the genomic counterparts.
The purpose of this study was twofold: (1) to develop and validate a new volume-based, quantitative imaging marker by integrating multi-parametric MR images for predicting survival of GBM patients; and (2) to investigate the relationship and potential synergy between the proposed imaging marker and underlying molecular characteristics of GBM.
Materials and methods

Study population
In this institutional review board-approved study, a total of 108 patients were retrospectively investigated. The inclusion criteria were: (1) pathologically confirmed diagnosis of GBM, (2) availability of preoperative T1-weighted contrast enhanced (T1-c) and diffusion-weighted (DW) images, and (3) availability of information about OS. The exclusion criteria were prior surgery and other treatments.
The majority of the study cohort, consisting of 92 patients from 1998 to 2011, was retrieved from the Cancer Imaging Archive (TCIA). We initially identified 98 patients from TCIA, of whom six were excluded due to poor image quality (such as motion, metal artifacts and RF inhomogeneity) as assessed by a neuroradiologist with over 10 years' experience (KKT). Furthermore, we searched patient records from 2004 to 2014 at the local institution using the same inclusion and exclusion criteria and found 31 patients. Fifteen of them were excluded because they did not have echo-planar T2-weighted images with zero diffusion weighting (b = 0 sec/mm 2 ), leading to 16 additional patients eligible for this study. The median follow-up duration was 10.9 months for the TCIA cohort and 9.6 months for the internal cohort.
We randomly split the TCIA cohort into two portions, where the first one containing approximately two-thirds of the patients (n = 62) was used as a discovery cohort. The remaining portion (n = 30) was combined with internal cohort (n = 16) to form the validation cohort (n = 46). The overall study design and patient cohorts are illustrated in Fig. 1 . Clinical and demographic information of the study population is listed in Table 1 .
Image acquisition
Among the 108 patients, the magnetic fields used to acquire the MR images were 1 T (n = 1), 1.5 T (n = 65), 3 T (n = 35) or unknown (n = 7). For the T1-c images, the sequence protocols were spin-echo (n = 77), gradient echo (n = 13) or T1-weighted fluid-attenuated inversion recovery (n = 18). The repetition time and echo time ranged respectively from 6-3,189 ms, and from 3-20 ms. The intra-slice voxel resolution varied from 0.43 to 1.02 mm, the slice thickness was between 2.5 mm and 5 mm, and the inter-slice gap was between 0 mm and 2.5 mm. For DW images, the b-values were 1,000 s/mm 2 (n = 103), 1,500 s/mm 2 (n = 5). Echo-planar T2-weighted images with zero diffusion-weighting (b = 0 s/mm 2 ) were acquired for all the patients (n = 108). The intra-slice voxel resolution, the slice thickness and the inter-slice gap of the DW images ranged from 0.86-1.8 mm, 3-7 mm and 0-1 mm, respectively.
Image processing
For each patient, we co-registered the MR images using the extensively validated software, elastix [27] . Specifically, we used the T1-c image as the reference and rigidly transformed and resliced the echo-planar T2-weighted image with zero diffusion weighting. However, for those cases having noticeable geometric distortion by automatic registration, in-house developed MATLAB software was used instead for manual registration. This process started with visually inspecting the T1-c image and the echo-planar T2-weighted image with zero diffusion weighting to identify slice pairs at the same locations. Then within each slice pair we manually selected landmark points at salient anatomical structures (e.g. ventricles) in both modalities and recorded their three-dimensional coordinates. Given the corresponding coordinates of the landmarks, we calculated an affine transformation function by leastsquare estimation to register the echo-planar T2-weighted image with zero diffusion weighting to the T1-c image. Finally, elastix was used to register the DW image to the T2-weighted image with zero diffusion weighting with affine transformation in order to correct for the eddy current distortion and motion effects [28] . The ADC maps were reconstructed from the registered images. Any voxel with negative ADC values due to measurement noise was set to zero and then imputed from its neighborhood.
Image normalization
Given the non-uniform imaging protocols and parameters of the MR images in the multi-institutional cohort, it is mandatory to normalize the image data acquired under different conditions. To this end, we proposed a novel standardization approach based on kernel density estimation (KDE). KDE is an unsupervised machine learning technique able to estimate the probability density function (PDF) underlying the observed data. It does not assume a parametric form for the PDF to be estimated and is therefore particularly suitable for charactering irregular (nonGaussian) distributions. Specifically, for each T1-c or ADC image, we applied the KDE to estimate the continuous PDF of the intensities for voxels within the entire brain parenchyma. We then normalized the image by dividing each voxel with the mode of this PDF (Fig. 2) . The rationale for this approach is that the mode represents the most frequently occurring voxel value in the image, which comes from the normal-appearing white matter that constitutes the majority of brain tissues. For PDF estimation we used the MATLAB code which used the Gaussian kernel and was able to automatically choose the kernel bandwidth based on the 'plug-in' KDE algorithm [29] . In order to avoid estimating the background noise, we set the interval on which the density estimate was constructed to be [max/50, max], where max denoted the maximum intensity of the image and used 10 8 meshes to discretize this interval. It should be noted that although some studies reported similar ADC values among scanners when identical image acquisition parameters were used [30] [31] [32] , the imaging parameters in our study were not consistent. Therefore, in order to minimize the effects of inter-scanner variations, we chose to normalize the ADC maps. ADC normalization was also performed in other studies [33] , where relative ADC maps were used to correlate with genetic and cellular GBM features. Fig. 1 Flow-chart showing the proposed study design. The Cancer Imaging Archive (TCIA) cohort was randomly split into the discovery cohort and a spin-off cohort, which was further combined with an internal cohort to construct the validation cohort. The proposed imaging marker was developed on the discovery cohort and its performance for OS prediction was also evaluated on the validation cohort. The subtype, mutation and methylation data associated with the TCIA cohort were used to correlate with the proposed imaging marker to show its biological relevance and complementarity to molecularlevel information
High-risk volume identification
The gross tumour volume (GTV), including both the contrastenhanced area and the bounded non-enhancing and necrotic regions, was segmented semi-automatically on T1-c images using MIPAV [34] . This process used the built-in levelset algorithm of MIPAV and entailed the operator moving the cursor around the boundary of the tumour which was then automatically captured. Manual correction was performed in eight cases where automatic segmentation failed. In order to assess the reproducibility of the segmentation as well as its impact on subsequent analyses, all tumours were independently delineated by two observers (SJR and YC). Dice and intraclass correlation coefficients were calculated for the two tumour segmentations.
After segmentation, we defined the high-risk volume (HRV) as the volume of the intratumoral subregion with both higher T1-c intensity and lower ADC. In order to obtain robust and meaningful thresholds to identify the HRV, we pooled the tumour voxels of all the patients in the discovery cohort for the normalized T1-c and ADC images, respectively. For each sequence we used the KDE to estimate their pooled PDFs and used the mode values as global cutoffs, hereafter denoted as t 1 and t 2 . The rationale for the use of mode is that statistically speaking, it is the most typical value of a certain population: any value above or below this value may be considered abnormally high or low. The HRV of an individual patient was defined as the volume of the tumour satisfying T1-c > t 1 and ADC < t 2 . Figure 2 illustrates the hierarchical flowchart for HRV identification. Once identified, the same thresholds were used to define the HRV for patients in the validation cohort. We examined whether HRV predicted OS in both discovery and validation cohorts. In addition to HRV, we computed the enhancing tumour volume (ETV), which we defined as the volume of the tumour satisfying T1-c > 1. The OS prediction performance of ETV was also evaluated.
Relationship between high-risk volume and molecular features
We investigated the associations between the proposed imaging marker (HRV) and four molecular subtypes of GBM, i.e. proneural, neural, classical and mesenchymal subtypes, which was obtained for 88 patients in the TCIA cohort from the UCSC Cancer Genomics Browser [35, 36] . Given the established role of MGMT methylation status for prognosis, we evaluated whether imaging-based HRV could provide complementary value in predicting survival. Information about MGMT methylation status was obtained for 61 patients Note.-Unless otherwise indicated, data are patient numbers † Data in parenthesis are censored patient numbers ‡ Data are mean ± standard deviation † † Data are median (range) * Missing data were imputed with median value in the TCIA cohort from a previous study [2] . Finally, we evaluated the relationships between HRV and the mutation status of nine genes that are known to have important functions in GBM, i.e. TP53, RB1, IDH1, PIK3R1, PTEN, PDGFRA, NF1, EGFR and PIK3CA [2] .
Statistical analysis
Survival prediction performances of the HRV were assessed by the concordance index (CI) [37] and Cox regression analysis. Survival differences among two or more patient groups were compared by the log-rank test as well as Kaplan-Meier analysis. One-way ANOVA was performed to analyse the correlation between a continuous variable (e.g. the HRV) and a nominal variable (e.g. molecular subtype). P values smaller than 0.05 were considered significant. All statistical analyses were done in the open-source statistical computing environment R.
Results
HRV predicted overall survival, independent of clinical factors and other imaging metrics in the overall cohort
In the discovery cohort, we determined the thresholds for defining the HRV to be t 1 = 1.429 and t 2 = 1.321 for the normalized T1-c and ADC intensities, respectively (Fig. 2) . Using this definition, HRV achieved a CI score of 0.642, and was significantly correlated with OS on univariate Cox regression analysis (P < 0.001). HRV remained as a significant predictor of OS (P < 0.001) when adjusted for clinical variables including age, Karnofsky Performance Scale (KPS), eloquent brain involvement (EBI, encoded as a binary variable) and conventional imaging metrics including ETV and minimum ADC ( Table 2 ). An optimal cutoff of 5.12 cm 3 for HRV stratified the discovery cohort in terms of OS (Fig. 3A , log-rank P = 0.009, hazard ratio = 2.413).
In the validation cohort, HRVachieved a similar CI of 0.653, and was again significantly correlated with OS (P = 0.038). Further, using the same cutoff derived from the discovery cohort, we stratified the validation cohort into short-and longsurvival groups, with a median survival of 9.3 and 13.7 months, respectively (Fig. 3B , log-rank P = 0.009, hazard ratio = 2.718). However, in the validation cohort alone, HRV was not significant (P = 0.20) in multivariate analysis, nor were any of the other analysed risk factors (P = 0.13-0.74), possibly due to the smaller size of this cohort. Therefore, in order to increase the statistical power, we combined the discovery and validation cohorts and performed multivariate analysis on this overall cohort again. The results showed that HRV was indeed a significant OS predictor in the overall cohort, independent of clinical factors and other imaging metrics.
Reproducibility of tumour segmentation and definition of HRV
The two independently delineated tumour volumes showed mostly high inter-observer agreement, with the Dice indices ranging from 0.623-0.985 (median: 0.948). Importantly, the HRVs computed from the two tumour segmentations were highly concordant (Supplemental Material, Fig. S1 ), with an Fig. 2 Diagrammatic representation of the procedure of high-risk volume identification. In Step 1, the T1-weighted contrast-enhanced (T1-c) and apparent diffusion coefficient (ADC) images for each patient were respectively normalized using the mode values of the intensity probability density function (PDF) estimates. In Step 2, the normalized intensities of the pixels within the segmented tumours (shaded in red) of all patients were pooled and two thresholds (t 1 , t 2 ) were respectively obtained as the mode values of the pooled intensity PDF estimates. In Step 3, high-risk volume (HRV) for each patient was defined as the volume of the tumour satisfying T1-c > t 1 and ADC < t 2 intra-class correlation of 0.994 (95% confidence interval (CI) = [0.990-0.994], P < 1E-16).
HRV-stratified patients within the proneural molecular subtype
One-way ANOVA showed that HRV was not significantly correlated with the four GBM subtypes (P = 0.1124).
However, we found that the tumours of the proneural subtype tended to have the smallest HRV, which was confirmed by pair-wise comparison with the other three subtypes (Fig. 4 , P = 0.014-0.038). Furthermore, HRV was significantly associated with OS within the proneural group (CI = 0.696, P = 0.003). Using the median (2.29 cm 3 ) as a cutoff, HRV stratified patients with proneural tumours into short -and long-survival groups, with a median survival of 6.4 and Note. Unless otherwise indicated, data in parenthesis are 95% confidence intervals HRV high-risk volume, KPS Karnofsky Performance Scale, ETV enhancing tumour volume, ADC apparent diffusion coefficient, EBI eloquent brain involvement * P < 0.05 ** P < 0.005 *** P <0.0005 12.3 months, respectively (Fig. 5A , log-rank P = 0.040, hazard ratio = 2.787). HRV did not stratify patients among other molecular subtypes.
HRV provided complementary information to MGMT methylation
HRV was not correlated with MGMT methylation status (P = 0.1746). Survival stratification based on MGMT methylation status alone trended toward significance (log-rank P = 0.072, hazard ratio = 1.762). However, by combining methylation status and HRV (using the median as the cutoff), we observed significantly different OS among the four groups (Fig. 5B , log-rank P = 0.011), i.e. methylated MGMT and low HRV (n = 7), methylated MGMT and high HRV (n = 6), unmethylated MGMT and low HRV (n = 21), and unmethylated MGMT and high HRV (n = 28). Of note, patients with unmethylated MGMT and high HRV had much shorter survival compared with the others (median survival: 9.3 vs. 18.4 months, log-rank P = 0.002).
Higher HRV was associated with NF1 and PIK3CA mutation HRV was significantly different between mutated and widetype groups for NF1 (P = 0.049) and PIK3CA (P = 0.028). Tumours with mutation in either NF1 or PIK3CA had higher HRV than those of the wild type (Supplemental Material, Fig. S2 ).
Discussion
In this study, we identified high-risk intratumoral subregions by using a data-driven approach and defined a volume-based imaging marker by integrating multi-parametric MR images of GBM. We found that HRV was prognostic for OS in two independent multi-institutional cohorts, and remained a significant predictor after adjusting for clinical factors and other imaging metrics. The predictive accuracy of HRV was higher than gross tumour volume, suggesting that analysis of intratumoral subregions may afford more reliable indicators of tumour burden compared with the whole tumour. HRV was also superior to minimum ADC, which points to the benefits of volume-based metrics versus conventional singlevoxel approaches. We used the kernel density estimation and mode approach under two scenarios: to obtain a patient-specific background voxel value for image normalization, and to find a populationlevel cutoff for defining the high-risk volume. In both scenarios, this approach has important advantages in that the mode Fig. 4 Boxplot shows that high-risk volume (HRV) was the smallest in the proneural subtype among the four glioblastoma (GBM) molecular subtypes. The P-value is for one-way ANOVA value is a more robust statistic of the pooled distribution compared with other commonly used summary statistics (e.g. mean, median or quantile values) [3, 6, 13] , which may be sensitive to variations in tumour segmentation [38, 39] . Compared with previous approaches that require manual selection of a region of interest for image normalization [33] , ours is fully automated and more robust.
Recent studies have used a quantitative radiomic approach to obtain comprehensive tumour phenotypes such as shape and texture. While further validation is warranted, this approach has shown promising results in identifying prognostic imaging markers in GBM, and appears to provide additional information beyond simple volume-based imaging metrics [20, 23, 40, 41] . Previously this approach has mostly been applied to the primary tumour to extract whole-tumour aggregate characteristics. It would be interesting to apply radiomics to the high-risk intratumoral subregions extracted in this work to derive further improvement in prognostic value [19] .
Our radiogenomic analysis revealed that the proposed imaging marker (HRV) was associated with several important molecular features of GBM. We showed that HRV was associated with OS and further stratified the proneural group. Compared with other molecular subtypes, the proneural group tended to harbour smaller HRV, which was correlated with longer survival. This is consistent with previous studies showing that the proneural molecular subtype had a better prognosis than other subtypes [2] .
We showed that higher HRV was associated with mutations in NF1 and PIK3CA, which are key genetic events driving the progression of GBM [2] . NF1 is a tumoursuppressor gene and frequently inactivated in GBM [2, 42] . It has been shown that NF1 mutation is highly enriched in the mesenchymal molecular subtype, a known aggressive GBM subtype with poor outcomes [2] . The PI3K signaling pathway is frequently dysregulated in GBM, and plays a critical role in proliferation, cellular metabolism and apoptosis [43] . Therapeutic agents inhibiting PI3K activity are under active development and have the potential for improvement in clinical outcome for GBM [44] . IDH1 mutation has been shown to be an independent prognostic factor in patients diagnosed with glioma including GBM [45] , but appeared to be not associated with HRV in our study (Fig. S2) , suggesting that they may be driven by differing biological processes.
Importantly, we showed that HRV provided complementary information to MGMT methylation status for survival prediction. Patients with unmethylated MGMT and high HRV had much shorter survival compared with others, while MGMT methylation status alone was not prognostic within our study cohort. This is consistent with a recent study [6] showing worse prognosis for patients with unmethylated MGMT and lower mean ADC. Taken together, these data support the notion that imaging-based HRV recapitulates tumour biology of GBM and potentially could provide additional prognostic information beyond genomic analysis.
Limitations of our study include the retrospective design and relatively small validation cohorts. The image data came from multiple institutions and were acquired with different imaging protocols and parameters, which might have influenced the image quantification. Nevertheless, we used careful image standardization techniques and robust image analysis to minimize the potential biases. Our findings warrant further validation in larger prospective cohorts. Intra-tumour genetic heterogeneity in GBM [46, 47] may confound the radiogenomic analyses. Because imaging has the unique capability of sampling the entire tumour and surrounding tissue, it would be intriguing to prospectively test the approach that combines image-guided stereotactic biopsy [48, 49] and the proposed method to identify high-risk intratumoral subregions, which might increase the likelihood of detecting the most aggressive part of a tumour.
Future studies would benefit from the incorporation of additional imaging modalities such as T2-weighted FLAIR and perfusion-weighted imaging for more comprehensive characterization of GBM such as surrounding edema/invasion [26] and blood volume/flow [3] . We also plan to test the ability of HRV to evaluate treatment response of GBM, in particular, to distinguish progression from pseudo-progression after chemoradiation therapy [50, 51] .
In conclusion, the volume of the high-risk intratumoral subregion on multi-parametric MRI predicts OS in GBM patients, and may provide complementary value to genomic information. We envision that the same approach could be applied to identify clinically and biologically relevant imaging markers in other cancer types.
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